FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 161 filers reported holding FATE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $9,151,934 | -65.8% | 907,930 | -29.6% | 0.13% | -61.4% |
| Q3 2022 | $26,744,000 | -8.6% | 1,288,858 | +1.4% | 0.34% | -5.3% |
| Q2 2022 | $29,263,000 | -37.0% | 1,270,565 | +0.6% | 0.36% | +5.9% |
| Q1 2022 | $46,473,000 | -35.6% | 1,262,866 | +1.6% | 0.34% | -10.3% |
| Q4 2021 | $72,209,000 | -0.1% | 1,242,843 | -0.3% | 0.38% | +22.6% |
| Q3 2021 | $72,301,000 | -17.2% | 1,246,570 | +21.6% | 0.31% | -9.4% |
| Q2 2021 | $87,313,000 | +88.6% | 1,025,519 | +82.6% | 0.34% | +50.7% |
| Q1 2021 | $46,304,000 | -5.3% | 561,595 | +4.5% | 0.23% | -18.3% |
| Q4 2020 | $48,890,000 | +152.8% | 537,664 | +10.1% | 0.28% | +62.6% |
| Q3 2020 | $19,341,000 | +13.2% | 488,399 | -7.4% | 0.17% | -23.7% |
| Q2 2020 | $17,085,000 | -58.5% | 527,311 | -71.5% | 0.22% | -42.0% |
| Q1 2020 | $41,134,000 | +156.4% | 1,852,018 | +125.9% | 0.39% | +52.6% |
| Q4 2019 | $16,044,000 | +22.9% | 819,810 | -2.5% | 0.25% | +9.1% |
| Q3 2019 | $13,052,000 | +26.4% | 840,430 | +65.2% | 0.23% | +14.3% |
| Q2 2019 | $10,329,000 | – | 508,841 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |